Business Context and Reporting Period
This Form 8-K filing by Neuphoria Therapeutics Inc. (NEUP) reports on events occurring as of December 31, 2025, with the report dated January 7, 2025. The filing details the termination of the Employment Agreement with Spyridon "Spyros" Papapetropoulos, M.D., who served as President and Chief Executive Officer (CEO) since January 5, 2023. Effective December 31, 2025, Mr. Papapetropoulos ceased his full-time executive duties but will remain a member of the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and contractual agreements.
- Severance Package: Mr. Papapetropoulos is entitled to severance equal to his annual base salary, target bonus, and medical insurance premiums.
- Payment Schedule: 50% of the gross severance is payable in calendar year 2025, with the balance paid in partial installments in 2026.
- Consulting Fees: Under a new Consulting Agreement effective January 1, 2026, Mr. Papapetropoulos will serve as interim CEO at a rate of $800 per hour.
- Consulting Cap: Services are capped at approximately 40 hours per month, not to exceed 20% of the hours performed as full-time CEO.
Material Changes Versus Prior Period
The primary material change is the transition of the CEO role from a full-time executive position to an interim consulting arrangement. This change coincides with the Company's pursuit of a "contemplated strategic transaction." Unlike the prior period where Mr. Papapetropoulos held full-time executive status with full benefits, his participation in employee benefit programs terminates immediately, except for rights to outstanding stock options which continue to vest.
Guidance, Outlook, and Risks
Outlook and Strategic Intent: The interim consulting arrangement is designed to support the execution of a contemplated strategic transaction and ensure a seamless transition. The Consulting Agreement will automatically terminate upon the earlier of twelve months from entry or the consummation of a strategic merger, change of control, or similar transaction.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks and uncertainties. The Company disclaims any obligation to update these statements. The specific terms of the strategic transaction are not disclosed in this filing.
Investor Verification Checklist
- Verify the exact amount of the severance package (annual base salary and target bonus) by reviewing the Company's most recent proxy statement or Form 10-K.
- Confirm the status and timeline of the "contemplated strategic transaction" mentioned as the reason for the interim CEO arrangement.
- Review the terms of the outstanding stock options held by Mr. Papapetropoulos to understand the vesting schedule post-termination.
- Monitor future filings for the consummation of a merger or change of control, which would trigger the automatic termination of the Consulting Agreement.